Eleven Biotherapeutics

Press Releases
 
Press Releases
Date Title and Summary View
September 22, 2017 -- Topline Three-Month Data from Phase 3 Registration Trial Expected in Mid-2018 -- CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing novel product candidates based on its Targeted Protein Therapeutics (T...
September 5, 2017 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing a broad pipeline of novel product candidates based on its Targeting Protein Therapeutics (TPTs) platform, today announced that Stephen Hurly, President and Chief Executive Officer, ...
August 14, 2017 -- Announced Data and Safety Monitoring Board Recommendation to Continue Phase 3 Registration Trial of Vicinium™ as Planned -- -- Entered Collaboration with National Cancer Institute and AstraZeneca to Evaluate Vicinium in Combination with Imfinzi™ (Durvalumab) in Patients with Non-Mus...
August 7, 2017 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing a broad pipeline of novel product candidates based on its Targeting Protein Therapeutics (TPTs) platform, today announced that it will host a live conference call and webcast at 8:00 ...
August 3, 2017 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing a broad pipeline of novel product candidates based on its Targeting Protein Therapeutics (TPTs) platform, today announced that Stephen Hurly, President and Chief Executive Officer, ...
June 12, 2017 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing a broad pipeline of novel product candidates based on its Targeting Protein Therapeutics (TPTs) platform, today announced that Stephen Hurly, President and Chief Executive Officer, ...
June 6, 2017 -- Cooperative Research and Development Agreement to Evaluate Activity of Eleven's Targeted Therapeutic Vicinium in Combination with the Immune Checkpoint Inhibitor Durvalumab -- CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical on...
June 1, 2017 Phase 3 Trial Enrollment Exceeds 50% Company Expects to Complete Patient Enrollment in 2H2017 and to Report Topline 3-Month Data in 2Q2018 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing...
May 17, 2017 -- Dr. Brooks Brings Substantial Experience in Leading Oncology Clinical Development Programs -- CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing a broad pipeline of novel product candidates based on its...
May 4, 2017 -- Continued Advancing Ongoing Phase 3 Registration Clinical Trial of Vicinium™ in Non-Muscle Invasive Bladder Cancer - -- Presented Preclinical Data at AACR Suggesting that Lead Compounds Induce Anti-Tumor Immune Response That Can Potentiate the Activity of Immuno-Oncology Agents -- ...
1
... NextLast
Add to Briefcase = add release to Briefcase
NASDAQ: EBIO
Price:
1.60
Change:
- 0.02
Day High:
1.73
Day Low:
1.55
Volume:
289,575
4:00 PM ET on September 22, 2017
Delayed at least 20 minutes.